NCT00189917View on ClinicalTrials.gov

Safety, Tolerability and Immune Response of IMVAMUNE (MVA-BN)Smallpox Vaccine in Patients With Atopic Disorders

PHASE1CompletedINTERVENTIONAL

Enrollment

60

Participants

Timeline

Start Date

April 30, 2004

Primary Completion Date

December 31, 2005

Conditions

Dermatitis, AtopicHay Fever

Interventions

BIOLOGICAL

IMVAMUNE (MVA-BN)

1x10E08 TCID50, subcutaneous vaccination

Trial Locations (1)

80802

Department of Infectious Diseases and Tropical Medicine, Munich

Sponsors

Lead Sponsor

Bavarian Nordic

All Listed Sponsors

collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

lead

Bavarian Nordic

INDUSTRY